IFN-β   Click here for help

GtoPdb Ligand ID: 4967

Synonyms: Avonex® (recombinant IFN-beta-1a) | fibroblast interferon | interferon beta
Immunopharmacology Ligand
Compound class: Endogenous peptide in human, mouse or rat
Comment: IFN-β is a type I IFN. The peptide sequence of the clinically used recombinant protein IFN-beta-1a is identical to that of the endogenous peptide.
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Recombinant IFN-βs such as IFN-β1b (recombinant human) and interferon-β1a are approved to treat multiple sclerosis (MS).

SARS-CoV-2 and COVID-19: a formuation of IFN-β that can be delivered directly to the lungs via a nebuliser (called SNG001) is being developed by Synairgen Research. SNG001 was initially designed to treat viral infection-related exacerbations in COPD patients (currently in Phase 2), but has been rapidly re-deployed for coronavirus infection. Preliminary data from Phase 2 study NCT04385095 are extremely encouraging- this news article by the European Pharmaceutical Review provides more details.